1. Home
  2. BRBI vs ADCT Comparison

BRBI vs ADCT Comparison

Compare BRBI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BRBI BR Partners S.A. ADSs

BRBI

BRBI BR Partners S.A. ADSs

SELL

Current Price

$8.29

Market Cap

191.9M

Sector

Finance

ML Signal

SELL

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

SELL

Current Price

$1.30

Market Cap

192.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BRBI
ADCT
Founded
2009
2011
Country
Brazil
Switzerland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.9M
192.7M
IPO Year
2025
2019

Fundamental Metrics

Financial Performance
Metric
BRBI
ADCT
Price
$8.29
$1.30
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
8.9K
★ 1.2M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 4.83%
N/A
EPS Growth
N/A
★ 30.86
EPS
★ N/A
N/A
Revenue
N/A
★ $81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$11.70
$25.89
P/E Ratio
$11.72
★ N/A
Revenue Growth
N/A
★ 14.85
52 Week Low
$6.80
$0.78
52 Week High
$16.61
$4.98

Technical Indicators

Market Signals
Indicator
BRBI
ADCT
Relative Strength Index (RSI) 40.28 42.27
Support Level $6.87 $0.97
Resistance Level $9.00 $1.45
Average True Range (ATR) 0.72 0.17
MACD 0.01 -0.04
Stochastic Oscillator 45.00 8.00

Price Performance

Historical Comparison
BRBI
ADCT

About BRBI BRBI BR Partners S.A. ADSs

BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: